Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trabedersen - Autotelic/Oncotelic Therapeutics

Drug Profile

Trabedersen - Autotelic/Oncotelic Therapeutics

Alternative Names: AP 2/09-DS; AP-12009; AP-2/09; OT-101; OT-201; Personalised dosing TGF-beta antisense; TGF-beta antisense

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antisense Pharma
  • Developer Autotelic; Mateon Therapeutics; Oncotelic; Oncotelic Therapeutics; Oncotelic Therapeutics - Dragon Overseas Capital (JV)
  • Class Antineoplastics; Antisense oligonucleotides; Antivirals; Immunotherapies; Oligodeoxyribonucleotides; Thionucleotides
  • Mechanism of Action Transforming growth factor beta2 inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II/III Malignant melanoma; Pancreatic cancer
  • Phase II COVID 2019 infections; COVID-19 pneumonia
  • Phase I Cancer
  • Clinical Phase Unknown Non-small cell lung cancer
  • Preclinical Diffuse intrinsic pontine glioma
  • No development reported Colorectal cancer; Ovarian cancer
  • Discontinued Anaplastic astrocytoma

Most Recent Events

  • 04 Mar 2024 Phase-II/III clinical trials in Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) (NCT06079346)
  • 17 Oct 2023 Oncotelic Therapeutics plans the phase IIb/III STOP-PC trial in Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease, Unresectable/Inoperable, Late stage disease) (IV) in December 2023 (NCT06079346)
  • 23 May 2023 Oncotelic Therapeutics plans a phase IIb/III trial for Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease) in 2H of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top